{"entity":{"id":"paper-nguyen-hpv-screen-treat-png-bmjgh-2022","kind":"paper","name":"Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea","aka":[],"tldr":"A model calibrated to Papua New Guinea found self-collected HPV screen-and-treat more effective and more cost-effective than visual inspection with acetic acid, and estimated it could prevent 23,000 to 29,000 deaths over 50 years if scaled to 70% coverage from 2023.","summary":"The authors note that Papua New Guinea has a high burden of cervical cancer but no national cervical screening programme. They calibrated the Policy1-Cervix model to the country, compared 38 strategies of self-collected HPV screen-and-treat and visual inspection with acetic acid (VIA), and estimated effectiveness, cost-effectiveness and budget impact, assuming HPV testing cost US$18.","asOf":"2026-11-11","links":[{"label":"DOI","url":"https://doi.org/10.1136/bmjgh-2021-007380"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35241461/"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"BMJ Global Health","year":2022,"doi":"10.1136/bmjgh-2021-007380","pmid":"35241461","authors":"Nguyen DTN, Simms KT, Keane A, et al.","paperType":"methods","findings":["Self-collected HPV screen-and-treat was more effective and more cost-effective than VIA; VIA screening was not effective or cost-effective.","Twice or three times lifetime screening was cost-effective at half of GDP per capita, with an incremental cost-effectiveness ratio of US$460 to US$656 per life-year saved.","If scale-up reached 70% coverage from 2023, it could prevent 33,000 to 42,000 cases and 23,000 to 29,000 deaths over the next 50 years."],"whatItMeans":"It gives Papua New Guinea its own estimate of what a national HPV screen-and-treat programme could achieve and what it would cost.","caveats":["A model: its outputs depend on assumed test performance, costs and coverage."]},"route":"/key-papers/paper-nguyen-hpv-screen-treat-png-bmjgh-2022/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"technology":[{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/"}],"institution":[{"id":"png-national-department-of-health","kind":"institution","name":"National Department of Health, Papua New Guinea","route":"/institutions/png-national-department-of-health/"}]}}